Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

Down Syndrome Clinical Trial

Official title:

A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride (Aricept®) in the Treatment of the Cognitive Dysfunction Exhibited by Children With Down Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00570128
• Other study ID #: E2020-A001-219
• Secondary ID: A2501059
• Status: Completed
• Phase: Phase 2
• Start date: November 16, 2007
• Est. completion date: September 5, 2008

Study information

• Verified date: March 2021
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether donepezil HCl is effective and safe in improving cognitive dysfunction exhibited by children and adolescents with Down syndrome (DS). Effectiveness will be measured by rating communication, daily living skills, and social skills and relationships in subjects aged 10 to 17.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 129
• Est. completion date: September 5, 2008
• Est. primary completion date: September 5, 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years to 17 Years

Eligibility

Inclusion Criteria:

• Ages 10 to 17 years old, weight more than or equal to 20 kg

• Male and female

• Vineland-II Adaptive Behavior Scales (VABS-II)/Parent/Caregiver Rating Form (PCRF) standard composite score greater than (>) 55

• Diagnosis of DS (trisomy 21) documented by chromosomal analysis (karyotyping). If such documentation is not available at screening, karyotyping will be performed with the screening labs and must be documented prior to baseline visit.

• Naïve to approved or unapproved cholinesterase inhibitors is preferred however, prior use of these medications is allowed, provided that the medication was discontinued at least 3 months prior to screening and that it was not discontinued for lack of tolerability or efficacy or for the sole purpose of enrolling the subject in the study.

• Subjects residing in the community

• Must be expected to complete all procedures scheduled during the Screening and Baseline visits including all efficacy and safety parameters.

• Must speak English and be verbal and able to be understood most of the time and must not use other forms of communication, signs, symbol boards or devices to supplement his/her communication ability

• Must have a parent or other reliable caregiver who agrees to accompany the subject to all clinic visits, provide information about the subject as required by the protocol, and ensure compliance with the medication schedule

• a Parent or Caregiver must be a constant and reliable informant with sufficient contact with the subject to have detailed knowledge of the subject's adaptive behavior in order to be able to complete the VABS-II/PCRF accurately. The same individual should complete the form at every visit.

• Should be in good general health with no medical conditions that are considered both clinically significant and unstable

• Clinical laboratory values within normal limits or abnormalities considered not clinically significant by the investigator and sponsor

• Stable Type I (insulin-dependent) or Type II diabetes are eligible provided they are monitored regularly prior to and during the study to ensure adequate glucose control (fasting blood glucose <140 milligram per deciliter (mg/dl) and glycosylated hemoglobin [hemoglobin A1c] <8 percent (%) at screening).

• Thyroid disease also may be included in the study provided they are euthyroid and stable on treatment for at least 3 months prior to screening.

• History of seizure disorder is allowed provided that subjects are on stable treatment for at least 3 months and have not had a seizure within the past 6 months.

• Independent in ambulation or ambulatory aided (example, walker or cane, wheelchair), vision and hearing (eyeglasses and/or hearing aid permissible) sufficient for achieving VABS-II/PCRF composite standard scores >55 and for cooperating with examinations and the Test of Verbal Expression and Reasoning (TOVER).

Exclusion Criteria:

• Ages <10 or >17 years

• Active or clinically significant conditions affecting absorption, distribution or metabolism of the study medication (example, inflammatory bowel disease, gastric or duodenal ulcers or severe lactose intolerance)

• Known hypersensitivity to piperidine derivatives or cholinesterase inhibitors

• Currently receiving cholinesterase inhibitors or who have received them in the 3 months prior to screening or with prior use >3 months prior to screening who stopped for lack of efficacy or tolerability

• No reliable parent or caregiver, or participants, or caregivers who are unwilling or unable to complete any of the outcome measures and fulfill the requirements of this study

• Clinically significant obstructive pulmonary disease or asthma untreated or not controlled by treatment within 3 months prior to screening

• Recent (less than or equal to 2 years) hematologic/oncologic disorders (mild anemia allowed)

• Evidence of active, clinically significant, and unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease

• Current Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnosis of Major Depressive Disorder (MDD) or any current primary psychiatric diagnosis other than DS (as per DSM-IV)

• Any condition which would make the subject or the caregiver, in the opinion of the investigator, unsuitable for the study

• Unsuitability which includes female subjects who have begun menstruation and are thus of child-bearing potential, who may be sexually active and who are not practicing an effective means of birth control.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Down Syndrome
• Syndrome

Intervention

Drug:
• Donepezil HCl
Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day [mL/day]) orally for participants with body weight (BW) 20 and less than (<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to <50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (>=) 50 kg liquid formulation (1 milligram per 1 milliliter [1 mg/1 mL]) (titrated to 0.1 to 0.2 milligram per kilogram per day [mg/kg/day] based on BW).
• Placebo
Liquid formulation matched to active treatment for oral administration.

Locations

Country	Name	City	State
United States	Child Neurology Associates, PC	Atlanta	Georgia
United States	Northwest Clinical Research Center	Bellevue	Washington
United States	Medical University of South Carolina, Division of Genetics and Developmental and Behavioral Pediatrics	Charleston	South Carolina
United States	Metrohealth Medical Center, Division of Psychiatry	Cleveland	Ohio
United States	Duke University Medical Center	Durham	North Carolina
United States	Hurley Medical Center	Flint	Michigan
United States	Neuropsychiatric Research Center of South West Florida	Fort Myers	Florida
United States	Saint Mayr's Health Care	Grand Rapids	Michigan
United States	Down Syndrome Clinic of Houston	Houston	Texas
United States	Rocky Mountain Pediatrics	Lakewood	Colorado
United States	Midwest Children's Health Research Institute, LLC	Lincoln	Nebraska
United States	Clinical Study Centers, L.L.C.	Little Rock	Arkansas
United States	Neufeld Medical Group, Inc.	Los Angeles	California
United States	Community Research Foundation	Miami	Florida
United States	Miami Children's Hospital, Brain Institute	Miami	Florida
United States	Miami Children's Hospital, Clinical Research Center	Miami	Florida
United States	Vanderbilt Children's Hospital	Nashville	Tennessee
United States	Children's Hospital and Research Center at Oakland	Oakland	California
United States	University of California, Irvine Medical Center, Department of Pediatrics	Orange	California
United States	Phoenix Children's Hospital	Phoenix	Arizona
United States	Washington University School of Medicine, Division of Genetics and Genomic Medicine	Saint Louis	Missouri
United States	Regions Hospital	Saint Paul	Minnesota
United States	Meridien Research	Saint Petersburg	Florida
United States	Alamo City Clinical Research, LLC	San Antonio	Texas
United States	Road Runner Research	San Antonio	Texas
United States	UCSD Pediatric Pharmacology Research Unit	San Diego	California
United States	Valko and Associates	Toledo	Ohio
United States	Tulsa Clinical Research LLC	Tulsa	Oklahoma
United States	Clinical Research Center of New Jersey	Voorhees	New Jersey
United States	Lazlo J. Mate, MD	West Palm Beach	Florida
United States	Medical Genetics and Neuro Development Center	Zionsville	Indiana

Sponsors (2)

Lead Sponsor	Collaborator
Eisai Inc.	Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-Domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form (VABS-II/PCRF) at Week 10-Last Observation Carried Forward (LOCF)	The VABS-II/PCRF instrument was used in this study to assess 3 domains (each with 3 sub-domains): communication (sub-domains: receptive, expressive, and writing), daily living skills (sub-domains: personal, domestic, community), and socialization (sub-domains: interpersonal relationships, play/leisure time, coping skills). Raw scores (2=always present, 1=sometimes present, 0=seldom or never present) rated by the parent/caregiver from each sub-domain were converted to standardized scores called V-scores, which are based on age and a national sample of normal children. Each sub-domain v-scale score ranged from 1 (weakness) to 24 (strength). V-scores for the 9 sub-domains were summed to obtain a composite V-score ranging from 9 to 216. Higher scores indicate a higher level of adaptive functioning. A positive change from baseline indicates an improvement in adaptive functioning. Composite V-scores have a mean (50th percentile) of 100 and a standard deviation (SD) of 15.	Baseline, Week 10
Secondary	Mean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form (VABS-II/PCRF) at Week 4 and 10-Observed Cases (OC)	The VABS-II/PCRF instrument was used in this study to assess 3 domains (each with 3 sub-domains): communication (sub-domains: receptive, expressive, writing), daily living skills (sub-domains: personal, domestic, community), and socialization (sub-domains: interpersonal relationships, play/leisure time, coping skills). Raw scores (2=always present, 1=sometimes present, 0=seldom or never present) rated by the parent/caregiver from each sub-domain were converted to standardized scores called V-scores, which are based on age and a national sample of normal children. Each sub-domain v-scale score ranged from 1 (weakness) to 24 (strength). V-scores for the 9 sub-domains were summed to obtain a composite V-score ranging from 9 to 216. Higher scores indicate a higher level of adaptive functioning. A positive change from baseline indicates an improvement in adaptive functioning. Composite V-scores have a mean (50th percentile) of 100 and a SD of 15.	Baseline, Week 4 and Week 10
Secondary	Mean Change From Baseline in Test of Verbal Expression and Reasoning (TOVER) Total Score at Week 4 and 10-OC	The TOVER is a participant-performance-based measure of expressive language function and verbal reasoning in response to questions about a series of stylized pictures showing identifiable scenarios. The 64-item test was specifically designed to assess language function in children and adults with down syndrome (DS) across a broad range of functional ability. The test used 23 multi-colored pictures to stimulate verbal responses to questions. The test was short (completed in 15 minutes) and fast-paced (2 to 4 questions per picture). Total score ranging from 0 to 64, was derived from 64 questions, where higher score indicates better functional ability.	Baseline, Week 4 and Week 10
Secondary	Mean Change From Baseline in Test of Verbal Expression and Reasoning (TOVER) Total Score at Week 10-LOCF	The TOVER is a participant-performance-based measure of expressive language function and verbal reasoning in response to questions about a series of stylized pictures showing identifiable scenarios. The 64-item test was specifically designed to assess language function in children and adults with DS across a broad range of functional ability. The test used 23 multi-colored pictures to stimulate verbal responses to questions. The test was short (completed in 15 minutes) and fast-paced (2 to 4 questions per picture). Total score ranging from 0 to 64, was derived from 64 questions, where higher score indicates better functional ability.	Baseline, Week 10